These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24186922)

  • 21. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Spyropoulos AC;
    N Engl J Med; 2013 May; 368(20):1945-6. PubMed ID: 23675665
    [No Abstract]   [Full Text] [Related]  

  • 22. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Alameddine R; Husari A
    N Engl J Med; 2013 May; 368(20):1944-5. PubMed ID: 23675666
    [No Abstract]   [Full Text] [Related]  

  • 23. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Derksen RJ; Mulder WM; Mulder JW
    N Engl J Med; 2013 May; 368(20):1945. PubMed ID: 23675667
    [No Abstract]   [Full Text] [Related]  

  • 24. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Vink R; Sohne M
    N Engl J Med; 2013 May; 368(20):1945. PubMed ID: 23675668
    [No Abstract]   [Full Text] [Related]  

  • 25. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia.
    Ng HJ; Than H; Teo EC
    Thromb Res; 2015 Jan; 135(1):205-7. PubMed ID: 24974053
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
    Bátorová A
    Vnitr Lek; 2009 Mar; 55(3):295-301. PubMed ID: 19378862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rivaroxaban. The first factor Xa inhibitor].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2008 Nov; 31(11):412-6. PubMed ID: 19055160
    [No Abstract]   [Full Text] [Related]  

  • 29. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
    Komotar RJ; Starke RM; Connolly ES
    Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E; Kubitza D; Misselwitz F
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanical Valve Thrombosis on Rivaroxaban: Are Novel Anticoagulants Really an Option?
    Kumar V; Kelly S; Raizada A; Yee J; Anuwatworn A; Stys A; Stys M
    Methodist Debakey Cardiovasc J; 2017; 13(2):73-75. PubMed ID: 28740586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model of heterotopic aortic valve replacement: a critique.
    Silverman NA
    J Surg Res; 2007 Aug; 141(2):133. PubMed ID: 17583741
    [No Abstract]   [Full Text] [Related]  

  • 35. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysis of thrombus located in the left atrial appendage. Is it the right time for a Xa factor inhibitor?
    Baran J; Zaborska B; Sikora-Frąc M; Stec S; Kułakowski P
    Kardiol Pol; 2013; 71(11):1210. PubMed ID: 24297727
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new era in secondary prevention after acute coronary syndrome.
    Roe MT; Ohman EM
    N Engl J Med; 2012 Jan; 366(1):85-7. PubMed ID: 22077849
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability.
    Dupree LH; Reddy P
    Ann Pharmacother; 2014 Dec; 48(12):1655-8. PubMed ID: 25169250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.